
Moberg Pharma AB (publ)
STO:MOB

Moberg Pharma AB (publ)
Gross Profit
Moberg Pharma AB (publ)
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Moberg Pharma AB (publ)
STO:MOB
|
Gross Profit
kr6.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Calliditas Therapeutics AB
STO:CALTX
|
Gross Profit
kr1.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Camurus AB
STO:CAMX
|
Gross Profit
kr1.7B
|
CAGR 3-Years
50%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Gross Profit
kr30.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
8%
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Gross Profit
kr935.5m
|
CAGR 3-Years
58%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Gross Profit
-kr20.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
Moberg Pharma AB (publ)
Glance View
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

See Also
What is Moberg Pharma AB (publ)'s Gross Profit?
Gross Profit
6.3m
SEK
Based on the financial report for Dec 31, 2024, Moberg Pharma AB (publ)'s Gross Profit amounts to 6.3m SEK.